Pharmaceutical company Crossject (Euronext Growth Paris:ALCJ) announced on Wednesday that it has received EUR6.9m in public funding from the French government's France 2030 plan to accelerate the development of its ZENEO Epinephrine auto-injector.

The funding, primarily grants with some subsidised loans, supports Crossject's innovative project to create a needle-free emergency treatment for severe allergic reactions.

ZENEO Epinephrine boasts a patented, sulphite-free formulation designed for reduced allergy risks and longer shelf life. The auto-injector ensures complete and rapid medication delivery.

Crossject aims to file for regulatory approval in Europe and the United States by 2026.